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INTRODUCTION
Proximal (Type 2) renal tubular acidosis (RTA) is a relatively
rare diagnosis, especially in adults. It is characterized by a
reduction in proximal bicarbonate reabsorption resulting
in urinary bicarbonate wasting. Proximal RTA can also be
associated with additional defects in proximal tubular
function including impaired reabsorption of phosphate,
glucose, uric acid, and amino acids. Generalized proximal
tubular dysfunction is termed Fanconi syndrome. While
there are primary causes of Fanconi syndrome including
sporadic and familial sources, this syndrome can also be
acquired. Two major culprits include monoclonal
gammopathies resulting in increased excretion of
immunoglobulin light chains and drug-induced nephrotoxicity to the proximal tubules.1 Tenofovir disoproxil
fumarate (TDF) is one such established nephrotoxic
agent associated with Fanconi syndrome, likely because
it is excreted through the kidney via active tubular
secretion.2-4 This case demonstrates a classic presentation
of tenofovir-induced Fanconi syndrome complicated by
respiratory repercussions of hypophosphatemia, and
also describes tenofovir alafenamide (TAF), a novel
formulation with reduced renal toxicity.

CASE PRESENTATION
A 63-year-old male and active smoker with human
immunodeficiency virus (HIV) on Atripla (efavirenz/
emtricitabine/TDF), intermittent alcohol abuse for
years, severe chronic obstructive pulmonary disease
(COPD) on no home oxygen presented with three
months of progressive dyspnea on exertion with
ambulatory dysfunction. The patient endorsed dyspnea
after ambulating 5-10 feet, with associated diffuse body
weakness. He noted frequent falls requiring use of a
walker. Over the six weeks prior to presentation, he had
been treated multiple times for presumed COPD
exacerbations with attempts to optimize his triple
inhaler therapy. He noted minimal improvement in his
respiratory symptoms despite these interventions.
Three months prior to presentation, he had been
functionally independent.
He was diagnosed with HIV 20 years prior, and had
achieved virologic suppression on Atripla without any side
effects. His history was also significant for coronary artery
disease with non-ST-elevation myocardial infarction in
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2012, prior stroke of the corona radiata in 2012,
hypertension, and Barrett’s esophagus. He endorsed
increased alcohol consumption in the last few months
to three drinks daily. He was an active smoker using
about half a pack of cigarettes per day. He denied
recreational drug use.
He reported no history of fever, chills, diarrhea, recent
travel, cough, sputum production, chest pain, lower
extremity swelling, orthopnea, or paroxysmal nocturnal
dyspnea.
On admission, the patient had a blood pressure of 110/70
mmHg with negative orthostatics, oxygen saturation of
96% on room air at rest but 79% with ambulation. He
subsequently developed hypoxia at rest as well. On
exam, the patient had diffusely decreased breath sounds
with no appreciable wheezes, crackles, or rales. He had
a regular S1 and S2 with no jugular venous distension or
peripheral edema. Neurological exam was grossly
unremarkable with 5/5 strength in all extremities and
intact sensation.
Labs were significant for serum bicarbonate 16 meq/L,
lactate 2.5 mmol/L, magnesium 0.8 mg/dL, phosphate
0.8 mg/dL, albumin 3.6 mg/dL, hemoglobin 8.3 g/dL,
CD4 173 with undetectable viral load. Urinalysis revealed
3+ glucose and pH 7.0. Urine phosphate 27 mg/dL and
creatinine 43 mg/dL.
Transthoracic echocardiogram demonstrated an
ejection fraction of 70% with normal left ventricular size
and function. Chest x-ray had no focal consolidation or
edema. Computed tomography (CT) angiography of the
chest was negative for acute pulmonary embolism.
Non-contrast CT head demonstrated no intracranial
hemorrhage, masses, or lesions.

DIFFERENTIAL DIAGNOSIS
This patient’s constellation of symptoms including
progressive shortness of breath, ambulatory dysfunction,
normal anion gap metabolic acidosis with hypophosphatemia and hypomagnesemia was initially challenging
to unify under one diagnosis.
His primary complaint of progressive shortness of breath
had a broad differential. Given his COPD history and
new oxygen requirement, progression of his underlying

disease was considered. The timeline of his symptoms
and objective physical exam did not support an acute
exacerbation. CT angiogram ruled out pulmonary
embolism. Given his history of coronary artery disease,
heart failure was also considered. However, this was not
corroborated by the patient’s physical exam and the
echocardiogram demonstrated normal ejection fraction.
Thus, we hypothesized that the patient’s progressive
shortness of breath was secondary to hypophosphatemia-induced respiratory muscle fatigue in the
setting of severe COPD.
The differential for the patient’s ambulatory dysfunction
included orthostatic hypotension, ethanol abuse, and a
new mass lesion or stroke given his prior cerebrovascular
history. His neurological exam was unremarkable,
orthostatics were normal, and CT head was unrevealing—
making his falls likely secondary to weakness as opposed
to an intracranial insult. Thus, there may have been a
component of hypophosphatemia-induced muscle
dysfunction.
Normal anion gap metabolic acidosis can be caused by
renal or gastrointestinal loss of bicarbonate, or with
decreased renal acid excretion. Loss of bicarbonate is
seen with Type 2 RTAs, diarrhea, carbonic anhydrase
inhibitors, and toluene inhalation (glue sniffing).5
The patient’s severe hypophosphatemia and hypomagnesemia was initially attributed to malnutrition in the
setting of alcohol abuse. However persistent deficiencies
despite intravenous repletion compounded with the
normal anion gap metabolic acidosis suggested
generalized proximal renal tubular dysfunction.

OUTCOME AND FOLLOW-UP
Fanconi syndrome was eventually suspected and
attributed to TDF. This suspicion was further supported by
a urine pH of 7, 3+ glucosuria, and increased fractional
excretion of filtered phosphate. Atripla (which contains
TDF) was discontinued and the patient was switched to
Descovy (emtricitabine and TAF) and Tivicay (dolutegravir).
The patient's generalized weakness, dyspnea, and hypoxia
improved with normalization of his serum bicarbonate,
phosphate, and magnesium. He was discharged with oral
phosphorus and magnesium supplementation. At his
most recent pulmonary follow-up, he had normal
ambulatory oximetry with increased functionality.

This is thought to be secondary to high circulating plasma
levels of tenofovir which is then excreted through the
kidney via active tubular secretion. Tenofovir alafenamide,
a novel oral prodrug of tenofovir, is metabolized to
tenofovir intracellularly rather than in plasma. This results
in higher intracellular concentrations of the active
metabolite compared to TDF. Consequently, the
therapeutic dose required for TAF is less than one-tenth
of the dose of TDF. 6 The resulting 90% reduction in
plasma tenofovir concentrations is believed to be
responsible for the improved renal safety demonstrated in
several phase 2 and 3 randomized-controlled trials.7 A
recent meta-analysis demonstrated that both
TDF-containing regimens and TAF-containing regimens
have high and comparable rates of virologic suppression.8
While promising, the long-term clinical significance of
TAF still needs to be assessed in prospective cohorts.

KEY POINTS
This case illustrates the renal side effects of TDF-induced
Fanconi syndrome, highlighting the manifestations of
hypophosphatemia. Recognizing this potential side effect
and switching patients to a TAF-containing regimen is
important to prevent renal injury.
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DISCUSSION
Tenofovir disoproxil fumarate, the first approved oral
prodrug of tenofovir, has been successfully used in
combination antiretroviral therapy for HIV treatment since
2001. However, as seen in this case and established in the
literature, TDF can cause clinically significant renal toxicity.
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